SNPMiner Trials (Home Page)
Report for SNP rs2307227
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
NCT03781752 ADHD Attention Deficit Hyperactivity Disorder Drug: Methylphenidate MeSH:Attention Deficit Disorder with Hyperactivity
HPO:Attention deficit hyperactivity disorder
In addition, the study team's in vitro studies have revealed that another common CES1 variant D203E (rs2307227) exhibited significantly impaired activity on MPH metabolism, although the effects on D203E on clinical response are in need of further elucidation.
Primary Outcomes
Description: The maximum plasma concentration achieved after dosing.
Measure: Maximum methylphenidate plasma concentration (Cmax), Time: up to 8 HoursSecondary Outcomes
Description: The time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination.
Measure: Time to maximum concentration (Tmax) Time: up 8 hoursDescription: Area under the plasma concentration-time curve from time zero to the last measurable concentration.
Measure: Area under the plasma concentration curve (AUClast) Time: up to 8 hoursDescription: Area under the plasma concentration-time curve from time zero to infinity.
Measure: Area under the plasma concentration curve (AUCinf) Time: up to 8 hours